Prostate Cell News 9.05 February 9, 2018 | |
| |
TOP STORYThe authors report a polycomb repressive complex 1-independent role of BMI1 that is critical for castration-resistant prostate cancer progression. BMI1 bound the androgen receptor (AR) and prevented MDM2-mediated AR protein degradation, resulting in sustained AR signaling in prostate cancer cells. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists developed an innovative approach for transgene expression in 3D organoids by combining single-cell encapsulation in Matrigel microbeads using a microfluidic device and electroporation. They demonstrated that direct electroporation of encapsulated organoids reaches up to 80% of transfection efficiency. [Nucleic Acids Res] Full Article Extracellular Redox State Shift: A Novel Approach to Target Prostate Cancer Invasion Altered expression of extracellular superoxide dismutase (ECSOD) and glutamate transporter (xCT) can lead to imbalance of the tumor microenvironment redox state and likely have a profound effect on cancer invasion. The authors investigated whether ECSOD and xCT could be therapeutic targets for prostate cancer invasion. [Free Radic Biol Med] Abstract LanCL1 Protects Prostate Cancer Cells from Oxidative Stress via Suppression of JNK Pathway Lanthionine synthase C-like protein 1 (LanCL1) promoted prostate cancer cell proliferation and helped protect cells from damage caused by oxidative stress. Suppression of LanCL1 by siRNA resulted in increased cancer cell apoptosis. [Cell Death Dis] Full Article MicroRNA-27a-5p Regulation by Promoter Methylation and MYC Signaling in Prostate Carcinogenesis Scientists elucidated the role of regulatory network between MYC and miRNAs in prostate carcinogenesis. MYC expression was found upregulated in prostate cancer cases and matched precursor lesions. [Cell Death Dis] Full Article Researchers performed RNA-seq analysis on cells treated with combinations of plumbagin and dihydrotestosterone, and analyzed differential gene expression, to gain insight into the interactions between androgen and plumbgin. [Sci Rep] Full Article The authors suggested TGFβ signaling and beta1 integrins as potential therapeutic targets in prostate cancer over-expressing caveolin-1. [Sci Rep] Full Article Researchers found that 17β-trenbolone induces androgen receptor-dependent cell proliferation in the human prostate cancer cell line, 22Rv1 in a concentration dependent manner. [Chemosphere] Abstract Investigators reported that SIRT3 inhibited the epithelial-mesenchymal transition and migration of prostatic cancer cells in vitro and their metastasis in vivo. [Exp Cell Res] Abstract Nc886 promoter methylation increased in tumor vs. normal prostate tissue, as well as in metastatic vs. normal prostate tissue. Additionally, nc886 promoter methylation correlated with prostate cancer clinical staging, including biochemical recurrence, Clinical T-value and Gleason score. [BMC Cancer] Full Article | |
| |
REVIEWSIntegrin Inhibitors in Prostate Cancer Scientists review the role of integrins inhibitors in prostate cancer (PCa) and their potential as therapeutic targets for PCa treatments. [Cancers] Full Article Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
SCIENCE NEWSApalutamide Delays Progression of Nonmetastatic, Castration-Resistant Prostate Cancer Treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy. The results of a multi-institutional, Phase III clinical trial of apalutamide – led by investigators from Massachusetts General Hospital and University of California, San Francisco – are receiving early release publication in the New England Journal of Medicine to coincide with a presentation. [Press release from Massachusetts General Hospital discussing research presented at American Society for Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium, San Francisco] Press Release | Abstract | |
| |
INDUSTRY NEWSAstellas Pharma Inc. and Pfizer Inc. announced results from the Phase III PROSPER trial in patients with non-metastatic castration-resistant prostate cancer. [Pfizer Inc.] Press Release The Janssen Pharmaceutical Companies of Johnson & Johnson announced new findings from the Phase III SPARTAN clinical trial that showed treatment with ERLEADA™, an investigational, next-generation androgen receptor inhibitor, decreased risk of metastasis or death by 72% and improved median metastasis-free survival by more than two years in patients with non-metastatic castration-resistant prostate cancer whose prostate specific antigen is rapidly rising, compared to placebo. [The Janssen Pharmaceutical Companies of Johnson & Johnson] Press Release The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the FDA has approved a new indication for ZYTIGA® in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer. [The Janssen Pharmaceutical Companies of Johnson & Johnson] Press Release University of California, Los Angeles researchers Dr. Leonard Marks and Shyam Natarajan will lead a $3.1 million research project grant awarded by the National Institutes of Health to advance the adoption of a promising new technology to treat men with prostate cancer. [University of California, Los Angeles] Press Release | |
| |
POLICY NEWSNew U.S. Budget Deal Includes More Funding for 2020 Census The latest short-term budget agreement that keeps the U.S. government running for another six weeks gives a much-needed boost to planning for the 2020 census. [ScienceInsider] Editorial NSF Requires Institutions to Report Sexual Harassment Findings The National Science Foundation (NSF) in Alexandria, Virginia, announced a new set of measures to combat sexual harassment by people working on the projects it funds. The steps may include suspending or eliminating research grants after an institution finds that a grantee committed harassment. [ScienceInsider] Editorial Breakthrough in Budget Negotiations Could Raise Spending for Science Top lawmakers in Congress announced a budget agreement that could produce substantial spending increases for research at key U.S. science agencies-and avoid a partial government shutdown. But the deal must still clear a few hurdles before it is finalized. [ScienceInsider] Editorial
| |
EVENTSNEW The New York Stem Cell Foundation (NYSCF) Conference 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Scientist Opportunities – Biomedical Research (Cedars-Sinai) NEW Postdoctoral Scientist – Cancer Research (Boehringer Ingelheim) Postdoctoral Fellow – Cancer Biology (Johns Hopkins University) Scientist – Cancer Biology (Dana-Farber Cancer Institute) Postdoctoral Fellow – Cancer Biology (University of Pennsylvania) Postdoctoral Fellow – Cancer Biology (Wake Forest Baptist Comprehensive Cancer Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|